GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4SC AG (LTS:0R6U) » Definitions » EBITDA Margin %

4SC AG (LTS:0R6U) EBITDA Margin % : -1,975.27% (As of Jun. 2024)


View and export this data going back to 2011. Start your Free Trial

What is 4SC AG EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. 4SC AG's EBITDA for the six months ended in Jun. 2024 was €-3.60 Mil. 4SC AG's Revenue for the six months ended in Jun. 2024 was €0.18 Mil. Therefore, 4SC AG's EBITDA margin for the quarter that ended in Jun. 2024 was -1,975.27%.


4SC AG EBITDA Margin % Historical Data

The historical data trend for 4SC AG's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4SC AG EBITDA Margin % Chart

4SC AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -578.78 -791.43 -62.20 -2,888.30 -2,496.05

4SC AG Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6,278.29 -615.33 -3,437.80 -1,820.34 -1,975.27

Competitive Comparison of 4SC AG's EBITDA Margin %

For the Biotechnology subindustry, 4SC AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


4SC AG's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4SC AG's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where 4SC AG's EBITDA Margin % falls into.



4SC AG EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

4SC AG's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-7.588/0.304
=-2,496.05 %

4SC AG's EBITDA Margin % for the quarter that ended in Jun. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-3.595/0.182
=-1,975.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


4SC AG  (LTS:0R6U) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


4SC AG EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of 4SC AG's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


4SC AG Business Description

Traded in Other Exchanges
Address
Fraunhoferstrasse 22, Planegg-Martinsried, DEU, 82152
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. Its pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development resminostat and Domatinostat. The geographic area of the company is Germany, the EU, and Other countries, and the majority of the revenue comes from Other Countries.

4SC AG Headlines

No Headlines